Agios Pharmaceuticals (AGIO) has drawn investor attention after recent trading moves, with the stock last closing at $27.96. You might be weighing how its current performance lines up with the company’s underlying fundamentals.

Recent moves around $27.96 come after a mixed stretch, with a 7 day share price return of 5.39% but a 90 day share price return of 35.95% and a 1 year total shareholder return decline of 15.83%, suggesting earlier momentum has faded even as some investors reassess the risk and potential of Agios’s pipeline.

If this kind of volatility has you looking wider in healthcare, it could be a good time to scan 25 healthcare AI stocks as another set of ideas to research.

With Agios trading around $27.96, showing fast annual revenue and net income growth but still reporting a net loss of $412.781 million, you have to ask: is this pipeline-focused biotech undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 23.9% Undervalued

Agios Pharmaceuticals' most followed narrative pegs fair value at $36.75 versus the recent $27.96 close, so the key question is how that gap is justified by its growth and profitability assumptions.

Upcoming potential FDA approval and commercial launch of PYRUKYND for thalassemia in the U.S. is set to significantly expand Agios' addressable market, driven by the high rate of disease diagnosis through newborn screening and well-defined patient populations, which should lift revenue growth in coming years.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that thalassemia call and the $36.75 fair value? Revenue growth assumptions, margin shifts and a premium future earnings multiple are all baked in, but the exact mix might surprise you.

Result: Fair Value of $36.75 (UNDERVALUED)

However, you also need to weigh that PYRUKYND concentration risk and the ongoing net loss of US$412.781 million, especially with safety scrutiny and R&D spend remaining a key consideration.

Another View: Revenue Multiple Sends A Different Signal

That 23.9% “undervalued” fair value at $36.75 sits awkwardly next to how the market is actually pricing Agios today. On a P/S of 30.2x, the stock trades at roughly 5 times the peer average of 6.3x and more than double the US biotechs average of 12.3x, while our fair ratio sits at 0x, suggesting very little fundamental support for this revenue multiple. With that kind of gap, are you looking at a genuine opportunity or a lot of optimism baked into every dollar of sales?

Build Your Own Agios Pharmaceuticals Narrative

If you see the story differently or just prefer to test the numbers yourself, you can build a fresh view in a few minutes: Do it your way.

A great starting point for your Agios Pharmaceuticals research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Agios has sharpened your thinking, do not stop here. A wider watchlist built from high quality ideas can make your research far more effective.

• Hunt for quality at a discount with our list of 53 high quality undervalued stocks that pair strong fundamentals with prices that may not fully reflect them yet.
• Secure steadier income potential by checking out 13 dividend fortresses, focused on companies offering yields that stand out for investors who care about cash flow.
• Protect your downside first by researching 85 resilient stocks with low risk scores, highlighting businesses that screen well on resilience and financial risk metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.